newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate Updates

Phase 1 clinical trial for KIN-2787, the company's investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate's China joint venture U.S. Food and Drug Administration granted Orphan Drug Designation for KIN-2787 for th